Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 16 · below the Ichimoku cloud · RSI 19 (oversold) · MACD below its signal · 8% above its 52-week low
None of the 29 investors followed here reported a position in CLPBF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CLPBF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.3 | -7.7 | -13.7 | -3.4 | -5.8 | -5.9 | 15.6 | 3.9 | -8.1 | -1.9 | −26.4% | ||
| 2025 | 4.4 | -3.5 | -4.6 | 2.1 | -8.6 | -6.8 | 2.2 | 4.5 | -12.8 | 7.1 | -0.1 | -7.4 | −22.7% |
| 2024 | -4.2 | 15.2 | 2.8 | -9.0 | 0.0 | -0.9 | 7.5 | 1.1 | 1.0 | -2.8 | 1.9 | -15.8 | −6.4% |
| 2023 | 7.2 | -5.1 | 12.1 | 9.5 | -11.7 | -1.3 | -1.8 | -9.4 | -6.4 | -0.2 | 1.3 | 9.6 | +0.6% |
| 2022 | -18.7 | 3.9 | -1.1 | -4.7 | -12.3 | -6.6 | 2.9 | 3.5 | -16.8 | 12.5 | 7.1 | -3.7 | −32.9% |
| 2021 | -2.1 | 2.3 | -1.9 | 9.9 | -5.8 | 1.2 | 8.2 | 3.9 | -8.1 | 1.6 | -0.9 | 3.5 | +10.6% |
| 2020 | 2.2 | 4.8 | -0.5 | 17.8 | 7.2 | -7.3 | 8.3 | 1.3 | -6.7 | -7.8 | 2.2 | 2.7 | +23.8% |
| 2019 | 1.1 | 6.0 | 11.7 | -3.2 | -1.2 | 7.0 | 5.3 | -0.6 | 4.4 | -2.3 | -1.2 | 5.7 | +36.6% |
| 2018 | 11.9 | -4.9 | 0.9 | -0.4 | 13.9 | 4.3 | 10.6 | -4.0 | -4.8 | -7.6 | -0.3 | -3.2 | +14.6% |
| 2017 | 4.9 | 2.9 | 5.5 | 13.6 | -4.8 | 6.4 | 0.0 | -5.9 | -3.0 | 10.8 | -8.1 | -0.3 | +21.4% |
| 2016 | 0.9 | -9.1 | 5.1 | -1.0 | 0.3 | -5.2 | 9.4 | -4.8 | 3.4 | -9.8 | -8.8 | 3.8 | −16.6% |
| 2015 | -8.1 | -5.9 | 1.3 | 5.2 | -8.3 | -10.2 | 5.5 | -2.5 | 3.6 | 1.3 | 7.7 | 1.9 | −10.1% |
| 2014 | 5.0 | 20.7 | -3.6 | 1.9 | 7.9 | 1.7 | -5.8 | -0.3 | -0.3 | -5.7 | 11.3 | 0.0 | +34.2% |
| 2013 | 6.6 | 0.0 | 4.3 | -2.3 | 6.5 | 0.1 | -2.3 | -1.9 | 4.0 | 14.5 | -2.1 | 2.2 | +32.3% |
| 2012 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 28.3 | 0.0 | 7.8 | 13.6 | +57.1% |
| 2011 | 0.0 | 1.9 | 0.0 | 6.5 | 0.0 | -0.3 | 3.3 | 0.0 | 0.0 | -4.0 | 8.8 | 0.0 | +16.7% |
| 2010 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 60.6 | 0.0 | 26.1 | -7.7 | +86.9% |
| 2009 | 0.0 | 0.0 | 0.0 | -4.2 | 0.0 | 0.0 | 0.0 | 16.5 | 0.0 | 0.0 | 0.0 | 0.0 | +11.6% |
| 2008 | -13.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.4 | -23.1 | 0.0 | 0.0 | 0.0 | 0.0 | −31.6% |
| 2007 | 0.0 | 0.0 | 21.5 | 0.0 | 0.0 | 0.0 | 0.0 | 12.9 | 0.0 | 0.0 | 0.0 | 0.0 | +37.2% |
No insider transactions reported for CLPBF.
No analyst coverage for this instrument.
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; Peristeen Plus, a transanal irrigation system; and Peristeen Light, a low-volume transanal irrigation. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as erectile dysfunction, urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.